Carboxylated hydroxyethyl starch: A novel polysaccharide for the delivery of doxorubicin

Chemical Biology and Drug Design

Volumn 85, Issue 5, 2015, Pages 653-658

  Paleos, Constantinos M ^a   Sideratou, Zili ^a   Theodossiou, Theodossis A ^a   Tsiourvas, Dimitris ^a  

^a NCSR Demokritos   (Greece)

Author keywords

doxorubicin; drug delivery; encapsulation; hydroxyethyl starch; hyperbranched polymer

Indexed keywords

AMINE; CARBOXYLIC ACID; DOXORUBICIN; HETASTARCH; MACROGOL; POLYSACCHARIDE; SUCCINIC ANHYDRIDE; ANTINEOPLASTIC AGENT; DRUG CARRIER; HETASTARCH DERIVATIVE;

ARTICLE; BIODEGRADABILITY; CELL NUCLEUS; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; ENCAPSULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER CELL LINE; PROTON TRANSPORT; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; FLUORESCENCE MICROSCOPY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; DOXORUBICIN; DRUG CARRIERS; HUMANS; HYDROXYETHYL STARCH DERIVATIVES; MICROSCOPY, FLUORESCENCE; POLYSACCHARIDES;

EID: 84926626142     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/cbdd.12447     Document Type: Article

References (22)

1. Boldt J., (2009) Modern rapidly degradable hydroxyethyl starches: current concepts. Anesth Analg; 108: 1574-1582.
2. Besheer A., Hause G., Kressler J., Mäder K., (2007) Hydrophobically modified hydroxyethyl starch: synthesis, characterization, and aqueous self-assembly into nano-sized polymeric micelles and vesicles. Biomacromolecule; 8: 359-367.
3. Brecher M.E., Owen H.G., Bandarenko N., (1997) Alternatives to albumin: starch replacement for plasma exchange. J Clin Apher; 12: 146-153.
4. Sommermeyer K., Eichner W., Frie S., Jungheinrich C., Scharpf R., Lutterbeck K., (2006) HAS-active ingredient conjugates. Patent Application, US 2006/0188472 A1, August 24.
5. Susa M., Iyer A., Ryu K., Hornicek F.J., Mankin H., Amiji M.M., Duan Z., (2009) Doxorubicin loaded polymeric nanoparticulate delivery system to overcome drug resistance in osteosarcoma. BMC Cancer; 9: 399-411.
6. Dellacherie É., (1996) Polysaccharides in oxygen-carrier blood substitutes, In:, Dumitriu S., editor. Polysaccharides in Medicinal Applications. New York, USA: Marcel Dekker; p. 525-544.
7. Schortgen F., Deye N., Brochard L., (2004) Preferred plasma volume expanders for critically ill patients: results of an international survey. Intens Care Med; 30: 2222-2229.
8. Baier G., Baumann D., Siebert J.M., Musyanovych A., Mailaender V., Landfester K., (2013) Suppressing unspecific cell uptake for targeted delivery using hydroxyethyl starch. Biomacromolecules; 13: 2704-2735.
9. Lasic D.D., Needham D., (1995) The "stealth" liposome: a prototypical biomaterial. Chem Rev; 95: 2601-2627.
10. Silvander M., Hansson P., Edwards K., (2000) Liposomal surface potential and bilayer packing as affected by PEG-lipid inclusion. Langmuir; 16: 3696-3702.
11. Kaasgaard T., Mouritsen O.G., Jørgensen K., (2001) Screening effect of PEG on avidin binding to liposome surface receptors. Int J Pharm; 214: 63-65.
12. Knop K., Hoogenboom R., Fischer D., Schubert U.S., (2010) Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew Chem Int Ed; 49: 6288-6908.
13. Styslinger T.J., Zhang N., Bhatt V.S., Pettit N., Palmer A.F., Wang P.G., (2012) Site-selective glycosylation of hemoglobin with variable molecular/weight oligosaccharides: potential alternative to PEGylation. J Am Chem Soc; 134: 7507-7515.
14. Gregoriadis G., Jain S., Papaioannou I., Laing P., (2005) Improving the therapeutic efficiency of peptides and proteins: a role for polysialic acids. Int J Pharm; 300: 125-130.
15. Fornari F.A., Randolph K., Yalowich C., Ritke M.K., Gewirtz D.A., (1994) Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells. Mol Pharmacol; 45: 649-656.
16. Hu F.-Q., Liu L.-N., Du Y.-Z., Yuan H., Hu F.-Q., (2009) Synthesis and antitumor activity of doxorubicin conjugated stearic acid-g-chitosan oligosaccharide polymeric micelles. Biomaterials; 30: 6955-6963.
17. Barry E., Alvarez J.A., Scully R.E., Miller T.L., Lipshultz S.E., (2007) Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management. Expert Opin Pharmacother; 8: 1039-1058.
18. Paleos C.M., Tsiourvas D., Sideratou Z., (2007) Molecular engineering of dendritic polymers and their application as drug and gene delivery systems. Mol Pharm; 4: 169-188.
19. Paleos C.M., Tsiourvas D., Sideratou Z., Tziveleka L.-A., (2010) Drug delivery employing multifunctional dendrimers and hyperbranched polymers. Expert Opin Drug Del; 7: 1387-1398.
20. Gosch C.I., Haase T., Wolf B.A., Kulicke W.-M., (2002) Molar mass distribution and size of hydroxyethyl starch fractions obtained by continuous polymer fractionation. Starch/Stärke; 54: 375-384.
21. Richardson S., Gorton L., (2003) Characterisation of the substituent distribution in starch and cellulose derivatives. Analyt Chem Acta; 497: 27-65.
22. Laginha K.M., Venwoert S., Charrois G.J., Allen T.M., (2005) Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors. Clin Cancer Res; 11: 6944-6949.